UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 14 von 81
Datensatz exportieren als...
BibTeX
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Cancer, 2017-07, Vol.123 (13), p.2482-2488
Kong, Jee Hyun
Winton, Elliott F.
Heffner, Leonard T.
Chen, Zhengjia
Langston, Amelia A.
Hill, Brittany
Arellano, Martha
El‐Rassi, Fuad
Kim, Audrey
Jillella, Anand
Kota, Vamsi K.
Bodó, Imre
Khoury, Hanna Jean
2017
Details
Autor(en) / Beteiligte
Kong, Jee Hyun
Winton, Elliott F.
Heffner, Leonard T.
Chen, Zhengjia
Langston, Amelia A.
Hill, Brittany
Arellano, Martha
El‐Rassi, Fuad
Kim, Audrey
Jillella, Anand
Kota, Vamsi K.
Bodó, Imre
Khoury, Hanna Jean
Titel
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Ist Teil von
Cancer, 2017-07, Vol.123 (13), p.2482-2488
Ort / Verlag
United States: Wiley Subscription Services, Inc
Erscheinungsjahr
2017
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
BACKGROUND To the authors' knowledge, the optimal frequency of monitoring after tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic myeloid leukemia (CML) has not been established. Data regarding the discontinuation of second‐generation TKIs used in first‐line treatment or after the failure of first‐line treatment with TKIs are limited. Herein, the authors report real‐world experience with “reduced frequency” molecular monitoring in patients with CML in all phases who discontinued treatment with imatinib, dasatinib, or bosutinib. METHODS The records of patients who discontinued TKIs were reviewed. Patients who discontinued TKIs were monitored prospectively on an intended schedule of monthly blood quantitative reverse transcriptase‐polymerase chain reaction for BCR‐ABL1 for 3 months, quarterly for 12 months, and every 6 months thereafter until loss of major molecular response (MMR). After loss of MMR, the TKI that previously was discontinued was reinitiated. RESULTS Between January 2010 and September 2015, a total of 24 patients in chronic (21 patients), accelerated (2 patients), and lymphoid blast (1 patient) phase discontinued imatinib (16 patients), dasatinib (5 patients), or bosutinib (3 patients) used in the front‐line treatment or beyond. Blood quantitative reverse transcriptase‐polymerase chain reaction for BCR‐ABL1 was performed 1.3 ± 0.7 times within the first 3 months (24 patients) and 2.7 ± 1.4 times in the following 12 months (18 patients). With a median follow‐up of 36.5 months (range, 3.2‐67.4 months), the probabilities of treatment‐free remission at 1 year and 2 years were 65.7% (95% confidence interval, 55.8%‐75.6%) and 59.7% (95% confidence interval, 49.1%‐70.3%), respectively. Loss of MMR was observed in 9 patients at a median of 2.8 months (range, 1.8‐14.2 months) after discontinuation of TKIs. CONCLUSIONS With the limitations of a small sample size, the results of the current study demonstrate that less frequent monitoring of BCR‐ABL1 does not appear to affect outcomes, and that discontinuation of TKIs used as first‐line treatment or beyond after resistance or intolerance to first‐line treatment appears feasible. Cancer 2017;123:2482–88. © 2017 American Cancer Society. Less frequent monitoring of BCR‐ABL1 after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia does not appear to affect outcomes. The discontinuation of tyrosine kinase inhibitors used as first‐line treatment or beyond after resistance or intolerance to first‐line treatment appears to be feasible.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.30608
Titel-ID: cdi_proquest_miscellaneous_1872873307
Format
–
Schlagworte
Adult
,
Aged
,
Aged, 80 and over
,
Aniline Compounds - therapeutic use
,
BCR/ABL1
,
Blood
,
Cancer
,
Chronic myeloid leukemia
,
Confidence intervals
,
Cyclin-dependent kinases
,
Dasatinib - therapeutic use
,
Deprescriptions
,
discontinuation
,
Diuretics
,
Female
,
Fusion Proteins, bcr-abl - genetics
,
Humans
,
Imatinib
,
Imatinib Mesylate - therapeutic use
,
Inhibitors
,
Intolerance
,
Leukemia
,
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood
,
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
,
Male
,
Middle Aged
,
Monitoring
,
Myeloid leukemia
,
Neoplasm Recurrence, Local - blood
,
Neoplasm Recurrence, Local - genetics
,
Nitriles - therapeutic use
,
Patients
,
Polymerase chain reaction
,
Protein Kinase Inhibitors - therapeutic use
,
Protein-tyrosine kinase
,
Quinolines - therapeutic use
,
Remission
,
Remission Induction
,
Retrospective Studies
,
Reverse Transcriptase Polymerase Chain Reaction
,
RNA-directed DNA polymerase
,
Tyrosine
,
tyrosine kinase inhibitor
,
Vaccines
,
Watchful Waiting - methods
,
Young Adult
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX